Skip to main content

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Former TAP Partner


Heidelberg, Germany, May 26, 2022 – Affimed N.V. (Nasdaq: AFMD), (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that three abstracts of clinical trial designs of its AFM24 innate cell engager (ICE®) have been published and will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on June 3-7, 2022 in Chicago, IL.

The Trial in Progress posters provide background information and introduce the study designs of the three ongoing AFM24 studies in which patients with a variety of EGFR-positive solid tumors are treated with AFM24 monotherapy or in combinations with either Roche’s checkpoint inhibitor, atezolizumab, or NKGen Biotech’s autologous NK cell product, SNK01.

Details about the Abstracts

The AFM24 monotherapy study (NCT04259450) abstract includes information about the dose-escalation phase of the study.

  • Authors: Omar Saavedra Hadea, Elena Garralda, Juanita Suzanne Lopez, Mark M. Awad, Jacob Stephen Thomas, Crescens Diane Tiu, Daniela Morales-Espinosa, Christa Raab, Bettina Rehbein, Gabriele Hintzen, Kerstin Pietzko, Paulien Ravenstijn, Michael Emig, Anthony B. El-Khoueiry

The AFM24 combination with atezolizumab study (NCT05109442) abstract details the trial design and rationale for the combination study of AFM24 and atezolizumab in patients with advanced EGFR-expressing solid tumors.

  • Authors: Omar Saavedra Hadea, Eric Christenson, Anthony B. El-Khoueiry, Andreas Cervantes, Christa Raab, Ulrike Gartner, Kerstin Pietzko, Gabriele Hintzen, Paulien Ravenstijn, Daniela Morales-Espinosa, Juanita Suzanne Lopez

The AFM24 combination study with SNK01 autologous natural killer cells (NCT05099549) includes information about the dose-escalation and dose-expansion phase of AFM24 in combination with SNK01 autologous NK cells in patients with advanced EGFR+ solid tumors.

  • Authors: Anthony B. El-Khoueiry, Paul Y. Song, Jennifer Rubel, Dorna Y. Pourang, Christa Raab, Gabriele Hintzen, Michael Emig, Pilar Nava-Parada

Press Release